Relevant bibliographies by topics / Codelet / Journal articles
To see the other types of publications on this topic, follow the link: Codelet.

Journal articles on the topic 'Codelet'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Codelet.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Truffelli, M., A. Petretto, G. Candiano, D. Giunti, T. Vigo, G. Gaggero, E. Bennicelli, M. Grassi, G. Zona, and P. Fiaschi. "P13.22 Menglia: an innovative approach to liquid biopsies in glioma patients." Neuro-Oncology 23, Supplement_2 (September 1, 2021): ii37. http://dx.doi.org/10.1093/neuonc/noab180.128.

Full text
Abstract:
Abstract BACKGROUND Gliomas are the second most frequent primary brain tumor. Since 2016 gliomas are classified according to histological, and molecular features such as IDH status and 1p19q codeletion. Recently oncological research has focused on liquid biopsies to reduce the need for invasive diagnostic tests. Cerebrospinal fluid (CSF) is the principal source of brain tumor biomarkers. Modern technologies currently allow us to analyze proteomic and metabolomic tumor profiles, in order to find new biomarkers without being constrained by a priori hypothesis. Several data from the literature also suggests that inflammatory cells and cytokines in tumors contribute to tumor growth, progression and immunosuppression. The possibility of simultaneously testing different inflammatory molecules on the biological fluids could lead to the identification of new biological markers with prognostic and predictive value for treatment response. STUDY OBJECTIVES - Identification of protein and/or lipid biomarkers specific to the glioma subgroup among those under analysis. - Identification of tumor group- and subgroup-specific CSF and/or serum inflammatory biomarkers among those tested. - Correlation of biomarkers with Progression Free Survival (PFS), Overall Survival (OS). ELIGIBILITY CRITERIA - Patients with a radiological suspected diagnosis of glioma eligible for surgery. - Age ≥ 18 years. - Availability of histological samples, CSF, blood and urine. - Patients with unconfirmed histological diagnosis of glioma will be excluded. - Patients who have never received any systemic or local treatment for CNS diseases. STUDY DESIGN This is a prospective monocentric study involving mass spectrometry analysis for characterization of proteins and metabolites and ELISA analysis for the characterization of different cytokines in parallel anonymized biological samples consisting of tumor tissue, CSF, blood and urine from glioma patients, divided into three different molecular subtypes: 1p19q codelet/IDH mutated, 1p19q non-codelet/IDH mutated and 1p19q non-codelet/IDH wt. Biological samples will be taken at surgery, at 24–48 h after surgery and every 3 months up to 1 year. The control group will include patients with subarachnoid hemorrhage or hydrocephalus, either undergoing external ventricular shunting or undergoing ventricular catheter placement/revision surgery. STUDY ANALYSIS Data interpretation will be based on a statistical analysis of the data, applying tools such as Principal Component Analysis (PCA) Weighted Correlation Network Analysis (WGNCA), Multiple Venn Diagram, T-Test, ANOVA, Clustering and Gene Ontology Enrichment, non-parametric Mann-Whitney test. For the assessment of clinical outcome, survival curves will be compared between different groups of patients who share a similar protein/metabolomic/inflammatory profile.
APA, Harvard, Vancouver, ISO, and other styles
2

Massett, Holly, Kurt A. Jaeckle, David M. Dilts, Andrea Denicoff, Erin Souhan, Jenny R. Hopkins, and Bhupinder Singh Mann. "Rapid online feedback to improve clinical trial accrual: CODEL anaplastic glioma (AG) (NCCTG/Alliance N0577) as a model." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 1596. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.1596.

Full text
Abstract:
1596 Background: Structured feedback from community oncologists regarding trial design rarely occurs. Survey templates were created to assess trial feasibility, design and scientific interest from the community, with the aim of improving accrual. We report results from a survey regarding redesign of the Phase III CODEL trial for newly diagnosed 1p/19q codeleted AG, which employed this approach. Methods: A field-tested, online survey template was tailored for CODEL and emailed to U.S. and international oncologists. The survey assessed (a) practice changes resulting from ASCO 2012 data from RTOG 9402 (abstract # 2008b) and EORTC 26951 (abstract # 2); (b) scientific interest in a redesigned trial; and (c) potential accrual issues. Respondents reviewed a brief trial concept and answered 15 questions anonymously via a web-based system. Results: 173 oncologists completed the survey over 2 weeks in Sept 2012(48% US, 52% Int’l; 35% med oncs, 31% rad oncs, 29% neuro-oncs). Results from the 2 prior studies substantially influenced clinicians’ treatment decisions for patients with newly diagnosed 1p19q codeleted AG--from only 9% recommending RT+PCV prior to the ASCO reports, to 46% after the results were presented. Previously, 25% recommended RT alone, and after ASCO, no one did. Most indicated strong interest in the revised CODEL research questions, trial design, randomization arms, and in re-opening the revised trial. The most interesting schema was a 3-arm design (selected by 45% of respondents): (RT + procarbazine, CCNU and vincristine chemotherapy [PCV]) vs. (RT + Temozolomide [TMZ]) vs. (TMZ alone), with neuro-oncs (49%) preferring it most, and rad oncs least (36%). The second most interesting choice (27%) was RT+PCV vs. RT+TMZ; the third choice (20%) was RT+TMZ vs. TMZ alone. Most (61%) felt patients would accept any arm. Respondents encountered eligible patients frequently enough to meet projected CODEL accrual goals. Conclusions: Survey findings significantly influenced decisions on how best to redesign the CODEL trial. Rapid, web-based surveys of community oncologists can provide important feedback regarding level of interest, which might facilitate timely accrual and trial completion.
APA, Harvard, Vancouver, ISO, and other styles
3

Foxley R., Juan. "Codelco." Observatorio Económico, no. 38 (January 1, 2010): 2–3. http://dx.doi.org/10.11565/oe.vi38.219.

Full text
Abstract:
La huelga de casi 6.000 trabajadores de Chuquicamata a principios de enero generó pérdidas por USD 16 millones a la compañía estatal y un costo superior a los USD 170 millones. Esto es, por dar un ejemplo, el doble de lo que el gobierno ha destinado a subsidiar el empleo juvenil. Pero si algo beneficioso dejó el conflicto fue recodarnos la profunda anomalía de una minera estatal que, tras la bonanza de precios del cobre, oculta ineficiencias graves que se pagan con menor ingreso fiscal para financiar programas públicos. Continuar leyendo...
APA, Harvard, Vancouver, ISO, and other styles
4

Tesileanu, C. Mircea S., Martin van den Bent, Thais Sabedot, Marc Sanson, Alba Brandes, Wolfgang Wick, Paul Clement, et al. "PATH-11. PROGNOSTIC SIGNIFICANCE OF EPIGENETIC SUBTYPES AND CpGs ASSOCIATED WITH PROGRESSION TO G-CIMP LOW IN THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON." Neuro-Oncology 22, Supplement_2 (November 2020): ii166. http://dx.doi.org/10.1093/neuonc/noaa215.693.

Full text
Abstract:
Abstract BACKGROUND Uncontrolled studies have suggested that methylation-based epigenetic subtypes can be used for prognostication of glioma. We used the prospective randomized CATNON trial to validate the clinical relevance of these epigenetic subtypes. METHODS The phase III CATNON trial randomized 751 adult patients with newly diagnosed 1p/19q non-codeleted anaplastic glioma to 59.4 Gy radiotherapy +/- concurrent and/or adjuvant TMZ. CNV data and methylation data were derived from Infinium MethylationEPIC arrays. Epigenetic subtyping and risk of progression to G-CIMP low were determined from random forest models and 7 specific CpGs (PMID: 29642018). IDH1/2 status was determined with a glioma-tailored NGS panel. Overall survival (OS) was measured from date of randomization. RESULTS Methylation analysis was performed on 654 tumors: 440 were IDH1/2mt, 204 IDH1/2wt and of 10 IDH1/2 status was unknown; 8 IDH1/2mt were 1p/19q codeleted. Based on methylation, tumors were classified as G-CIMP high (n=409), G-CIMP low (n=19), codel-like (n=18), mesenchymal-like (n=107), classic-like (n=48), and PA-like tumors (n=53). Median OS between these epigenetic subtypes varied considerably: codel-like 9.1 yrs, G-CIMP high 9.5 yrs, G-CIMP low 2.8 yrs, mesenchymal-like 1.3 yrs, classic-like 1.6 yrs, and PA-like 2.8 yrs. The difference in OS of the IDH1/2mt astrocytoma subgroup patients was prominent [G-CIMP low vs G-CIMP high: HR 4.12, 95% CI 2.37-7.19, p < 0.001]. Within the IDH1/2mt G-CIMP high astrocytoma patients, 115 tumors were predicted to have risk of progression to G-CIMP low and patients with such tumors indeed had poorer survival [risk vs no-risk: HR 1.59, 95% CI 1.10-2.31, p = 0.02]. Median OS in G-CIMP high tumors with (n=37) and without (n=366) CDKN2A/B HD was 3.3 yrs versus not reached [p< 0.001], in G-CIMP low tumors it was 1.2 yrs (n=6) versus 4.4 yrs (n=12) [p=0.008]. CONCLUSIONS In IDH1/2mt anaplastic astrocytoma, G-CIMP status and CDKN2A/B HD are of independent prognostic value.
APA, Harvard, Vancouver, ISO, and other styles
5

Pan, Cong, Minyan Lu, and Biao Xu. "An Empirical Study on Software Defect Prediction Using CodeBERT Model." Applied Sciences 11, no. 11 (May 23, 2021): 4793. http://dx.doi.org/10.3390/app11114793.

Full text
Abstract:
Deep learning-based software defect prediction has been popular these days. Recently, the publishing of the CodeBERT model has made it possible to perform many software engineering tasks. We propose various CodeBERT models targeting software defect prediction, including CodeBERT-NT, CodeBERT-PS, CodeBERT-PK, and CodeBERT-PT. We perform empirical studies using such models in cross-version and cross-project software defect prediction to investigate if using a neural language model like CodeBERT could improve prediction performance. We also investigate the effects of different prediction patterns in software defect prediction using CodeBERT models. The empirical results are further discussed.
APA, Harvard, Vancouver, ISO, and other styles
6

Núñez Batalla, Faustino, Carmen Jáudenes Casaubón, Jose Miguel Sequí Canet, Ana Vivanco Allende, and José Zubicaray Ugarteche. "Recomendaciones CODEPEH 2014." REVISTA ESPAÑOLA DE DISCAPACIDAD 3, no. 1 (June 2015): 163–86. http://dx.doi.org/10.5569/2340-5104.03.01.09.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pareira, Eriel, Kentaro Ohara, Makoto Shibuya, Yu Nakagawa, Kazunari Yoshida, and Hikaru Sasaki. "PATH-58. REAPPRAISAL OF HISTOLOGICAL FEATURES AND MOLECULAR ANALYSIS OF LOWER GRADE GLIOMAS AND ASSOCIATION WITH OVERALL SURVIVALS." Neuro-Oncology 21, Supplement_6 (November 2019): vi156. http://dx.doi.org/10.1093/neuonc/noz175.653.

Full text
Abstract:
Abstract INTRODUCTION Based on WHO 2016 classification of grade II and III glioma (lower grade glioma/LrGG), the pathological diagnosis of oligodendroglioma is associated with IDH mutation status and 1p/19q codeletion. It was reported that the classical oligodendroglioma features closely related to the presence of 1p/19q codeletion. In this study, we compared histology of oligodendroglial features with molecular prognostic factors such as ATRX, TERT, IDH1/2 and copy number aberrations and their relations with patients’ prognoses. METHODS In this study, we analyzed 94 cases of primary LrGG resected in 1990 to 2016 in Keio University Hospital, Japan. Using WHO 2007 classification of LrGG, we re-diagnosed the tumors based on their histological features and compared them to their initial diagnoses (made by the pathologists on the time of resections). The presence of classic for oligodendroglioma (CFO) features were closely documented. ATRX mutation was analyzed by immunohistochemistry. IDH1/2 and TERT mutation status were analyzed using Sanger sequence. Copy number aberrations analyzed using comparative genomic hybridization (CGH). In addition, we analyzed IDH-mut/codeleted tumors with cancer genetic panel. RESULTS Re-diagnosis shown there is a shift of trend toward oligodendroglioma diagnoses from astrocytoma and a trend of change from grade II to grade III. IDH-mut/codel tumors shown no correlation between CFO and molecular prognostic factors nor CNAs but there was correlation between overall survival and molecular factors such as CIC (p= 0.046) and FUBP1(p= 0.03). IDH-mut/non-codel tumors shown no correlation between CFO and overall survival but ATRX and gain of 8q were found to be correlated with pathological diagnosis. CONCLUSION There is a lot of change in histological diagnosis of oligodendroglioma from each eras. IDH-mut/codel tumors shown there is correlation between FUBP1 and CIC with overall survivals. IDH-mut/noncodel tumors shown there is correlation between gain of 8q with overall survivals.
APA, Harvard, Vancouver, ISO, and other styles
8

Rajeevan, Mangalathu S., Sonya Patel, Tengguo Li, and Elizabeth R. Unger. "NanoString Technology for Human Papillomavirus Typing." Viruses 13, no. 2 (January 27, 2021): 188. http://dx.doi.org/10.3390/v13020188.

Full text
Abstract:
High-throughput HPV typing assays with increased automation, faster turnaround and type-specific digital readout would facilitate studies monitoring the impact of HPV vaccination. We evaluated the NanoString nCounter® platform for detection and digital readout of 48 HPV types in a single reaction. NanoString (NS) used proprietary software to design CodeSets: type-specific probe pairs targeting 48 HPV types and the globin gene. We tested residual DNA extracts from epidemiologic specimens and defined samples (HPV plasmids at 10 to 104 copies/reaction) directly (No-PCR) as well as after L1 consensus PCR of 45 (PCR-45) or 15 cycles (PCR-15). Assay and interpretation followed NS recommendations. We evaluated analytic performance by comparing NanoString results for types included in prior assays: Roche Linear Array (LA) or HPV TypeSeq assay. No-PCR results on 40 samples showed good type-specific agreement with LA (k = 0.621) but sensitivity was 65% with lower limit of detection (LOD) at 104 plasmid copies. PCR-45 results showed almost perfect type-specific agreement with LA (k = 0.862), 82% sensitivity and LOD at 10 copies. PCR-15 results on 75 samples showed substantial type-specific agreement with LA (k = 0.796, 92% sensitivity) and TypeSeq (k = 0.777, 87% sensitivity), and LOD at 10 copies of plasmids. This proof-of-principle study demonstrates the efficacy of the NS platform with HPV CodeSet for type-specific detection using a low number of PCR cycles (PCR-15). Studies are in progress to evaluate assay reproducibility and analytic validation with a larger number of samples.
APA, Harvard, Vancouver, ISO, and other styles
9

Habermann, Ted. "Mapping ISO 19115-1 geographic metadata standards to CodeMeta." PeerJ Computer Science 5 (February 4, 2019): e174. http://dx.doi.org/10.7717/peerj-cs.174.

Full text
Abstract:
The CodeMeta Project recently proposed a vocabulary for software metadata. ISO Technical Committee 211 has published a set of metadata standards for geographic data and many kinds of related resources, including software. In order for ISO metadata creators and users to take advantage of the CodeMeta recommendations, a mapping from ISO elements to the CodeMeta vocabulary must exist. This mapping is complicated by differences in the approaches used by ISO and CodeMeta, primarily a difference between hard and soft typing of metadata elements. These differences are described in detail and a mapping is proposed that includes sixty-four of the sixty-eight CodeMeta V2 terms. The CodeMeta terms have also been mapped to dialects used by twenty-one software repositories, registries and archives. The average number of terms mapped in these cases is 11.2. The disparity between these numbers reflects the fact that many of the dialects that have been mapped to CodeMeta are focused on citation or dependency identification and management while ISO and CodeMeta share additional targets that include access, use, and understanding. Addressing this broader set of use cases requires more metadata elements.
APA, Harvard, Vancouver, ISO, and other styles
10

Keung Ng, Ho, Kay Ka-Wai Li, Tathiane M. Malta, Zhi-feng Shi, and Houtan Noushmehr. "Combined epigenetic signature and gene copy number variations in IDH-mutant glioblastomas showed varied risk stratification." Neuro-Oncology 21, Supplement_4 (October 2019): iv2. http://dx.doi.org/10.1093/neuonc/noz167.006.

Full text
Abstract:
Abstract The number of IDH-mutant glioblastoma examined in the literature and TCGA is few. We used Infinium MethylationEPIC BeadChip array to classify 64 IDH-mutant-GBM into methylation groups. Gene copy number variations were determined from methylation. 53.1%, 35.9%, and 10.9% of tumors belonged to G-CIMP-high, G-CIMP-low and codel groups respectively. G-CIMP-low group of IDH-mutant glioblastoma was associated with worse survival as compared to G-CIMP-high (p=0.005) and Codel groups (p=0.009). CDKN2A deletion (24/64; 37.5%) was the most common gene copy number variation, and was significantly associated with GCIMP-low subgroup (p=0.001). Amplification of MET was identified in 3/64 (9.4%), CCND2 11/64 (17.2%), PDGFRA 9/64 (14.1%), CDK4 8/64 (12.5%) and EGFR 8/64 cases (12.5%). Both CDKN2A deletion (p=0.008) and MET amplification (p<0.001) were associated with poor survival. Combined methylation signature and gene copy number variations separated IDH-mutant glioblastoma into Group 1 (codeleted), Group 2 (GCIMP-high without CDKN2A deletion), Group 3 (GCIMP-high with CDKN2A deletion), Group 4 (GCIMP-low without CDKN2A and MET alterations), and Group 5 (GCIMP-low with CDKN2A and/or MET alterations). Group 1 had a favorable overall survival with a median survival of 1240 days. Groups 2, 3, and 4 exhibited an intermediate outcome with a median survival of 536, 619, and 655 days respectively. Group 5 exhibited a poor outcome with a median survival of 255 days. Groups based on combined methylation signature and CDKN2A/MET status are an independent prognostic factor. Conclusion: IDH mutant glioblastomas should be stratified for risk with combined epigenetic signature and CDKN2A/MET status and some cases have unfavorable outcomes.
APA, Harvard, Vancouver, ISO, and other styles
11

Lhomme, M., and R. Ducatelle. "Vergelijkende erfelijke en pathogenische kenmerken van hypertrofische cardiomyopathie bij de kat en de mens." Vlaams Diergeneeskundig Tijdschrift 84, no. 2 (April 30, 2015): 73–79. http://dx.doi.org/10.21825/vdt.v84i2.16609.

Full text
Abstract:
Hypertrofische cardiomyopathie (HCM) wordt gekenmerkt door een hypertrofisch, nietgedilateerd linkerventrikel. Met een prevalentie van ongeveer 0,2% bij mensen en 15% bij katten is dit één van de meest voorkomende hartafwijkingen. In het merendeel van de gevallen is de aandoening erfelijk bepaald, maar ze kan ook verworven zijn. De klinische symptomen zijn variabel. Genotypisch aangetaste individuen kunnen (ernstige) symptomen van hartfalen vertonen of zelfs abrupt sterven, maar ze kunnen ook gedurende heel het leven asymptomatisch blijven. Er zijn bij de mens reeds meer dan 1400 polymorfismen gedetecteerd in dertien genen die coderen voor sarcomeereiwitten in het hart. Een deel van deze hebben een invloed op het aangemaakte eiwit en zijn, samen met modificerende genen en omgevingsfactoren, verantwoordelijk voor de ontwikkeling van hypertrofische cardiomyopathie. Bij de kat werden tot op heden slechts drie mutaties geïdentificeerd in een gen dat codeert voor één sarcomeereiwit. Voor deze drie mutaties bestaan reeds commerciële diagnostische testen. Deze mutaties zijn slechts verantwoordelijk voor een kleine fractie van de gevallen van HCM bij de kat. Wil men preventief ingrijpen, dan is het van belang om zo veel mogelijk oorzakelijke mutaties te kennen. Er zijn veel raakpunten tussen de feliene en humane vorm van hypertrofische cardiomyopathie. Zowel de manier van overerven (autosomaal) als de klinische verschijning en de histopathologische veranderingen komen overeen tussen de verschillende species. Er is echter nog te weinig bekend over de sarcomeereiwitten en hun mutaties om informatie te extrapoleren van mens naar kat en vice versa.
APA, Harvard, Vancouver, ISO, and other styles
12

Cluceru, Julia, Paula Alcaide-Leon, Yannet Interian, Valentina Pedoia, Joanna Phillips, Devika Nair, Tracy Luks, Javier Villanueva-Meyer, and Janine Lupo. "NIMG-36. AUTOMATIC STRATIFICATION OF ENHANCING AND NON-ENHANCING GLIOMAS INTO GENETIC SUBTYPES USING DEEP NEURAL NETWORKS AND DIFFUSION-WEIGHTED IMAGING." Neuro-Oncology 22, Supplement_2 (November 2020): ii155. http://dx.doi.org/10.1093/neuonc/noaa215.649.

Full text
Abstract:
Abstract INTRODUCTION Current WHO guidelines emphasize classification of diffuse gliomas by genetic alterations into three subgroups: 1) IDH-wildtype; 2) IDH-mutant, 1p/19q-codeleted; and 3) IDH-mutant, 1p/19q-non-codeleted. Non-invasive genetic characterization can benefit patients with inoperable lesions or who are administered molecularly-targeted therapy before surgery. Prior studies that use anatomical images and convolutional neural networks (CNNs) to distinguish either IDH-mutant from IDH-wildtype tumors, or 1p/19q-codeleted from non-codeleted tumors have resulted in misclassification of nonenhancing IDH-wildtype and enhancing IDH-mutant tumors. This study investigated the benefit of a priori separation of enhancing from nonenhancing lesions and the inclusion of ADC maps from diffusion MRI to genetic subgroup classification. METHODS 3D T2-weighted, T2-FLAIR, and post-contrast T1-weighted images were acquired preoperatively from 254 patients with newly-diagnosed gliomas. IDH1R132H mutations[VJ1] [CJ2], 1p19q-codeletions, ATRX alterations, and p53 mutations were assessed from the resected tissue to determine subtype stratification: IDH-wildtype (n=95), IDH-mutant, 1p/19q-codeleted (n=62), and IDH-mutant, non-codeleted (n=97). 3-channel input images were constructed for each patient using T2-FLAIR, T1-post-contrast, and either T2-weighted or ADC images. Three VGG-16 CNNs pre-trained on ImageNet were re-trained for: 1) lesions without enhancement, 2) enhancing lesions, and 3) all lesions together[VJ3]. RESULTS A network trained on only enhancing lesions predicted the IDH-wildtype subtype with the highest class accuracy (ADC 94%, T2-weighted 100%) compared to using all lesions combined (ADC 90%, T2-weighted 90%). Models trained using non-enhancing lesions and ADC yielded the highest accuracy classifying 1p/19q-codeleted/non-codeleted subgroups (87%/90% for the non-enhancing network vs 83%/81% for combined network). CONCLUSIONS Our results support a strategy that first considers whether a lesion is enhancing when predicting molecular subgroup and includes ADC if the lesion is non-enhancing. Analysis is underway to test this model framework on independent TCIA data.
APA, Harvard, Vancouver, ISO, and other styles
13

Bakholdin, V. S., D. A. Gavrilov, V. A. Dobrikov, and V. F. Ivanov. "Codeless Acquisition of GNSS Signals." Gyroscopy and Navigation 11, no. 1 (January 2020): 68–76. http://dx.doi.org/10.1134/s2075108720010058.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Leite, Rogério Cezarde Cerqueira. "CODETEC – Companhia de Desenvolvimento Tecnológico." Revista Brasileira de Inovação 7, no. 2 (June 24, 2008): 483. http://dx.doi.org/10.20396/rbi.v7i2.8648972.

Full text
Abstract:
A concepção da CODETEC nasceu de um paradoxo fértil como costuma acontecer com inovações. À época era tradicional na universidade brasileira a repulsa ao uso de meios pertencentes a universidades para atividades pré-empresariais. Enquanto em muitas das universidades americanas era comum a tolerância quanto ao uso de espaço, equipamentos, intelectos e mesmo mão-de-obra técnica para atividades precursoras à implantação de indústrias. Uma maneira de contornar esse conflito foi oficializá-lo. Os exemplos flagrantes, extremamente construtivos observados em universidades americanas de onde surgiam importantes empreendimentos de conseqüências econômicas marcantes, consentiam na aceitação de riscos inerentes a atividades estranhas à tradição universitária corrente. Foi com essa consciente certeza de conflito de interesse que foi concebida a CODETEC.
APA, Harvard, Vancouver, ISO, and other styles
15

Speidel, U. "Constructing finite pseudo-random strings using codeset-based entropy measures." IEE Proceedings - Circuits, Devices and Systems 153, no. 4 (2006): 315. http://dx.doi.org/10.1049/ip-cds:20050168.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Watson, Jessica, Brian D. Nicholson, Willie Hamilton, and Sarah Price. "Identifying clinical features in primary care electronic health record studies: methods for codelist development." BMJ Open 7, no. 11 (November 2017): e019637. http://dx.doi.org/10.1136/bmjopen-2017-019637.

Full text
Abstract:
ObjectiveAnalysis of routinely collected electronic health record (EHR) data from primary care is reliant on the creation of codelists to define clinical features of interest. To improve scientific rigour, transparency and replicability, we describe and demonstrate a standardised reproducible methodology for clinical codelist development.DesignWe describe a three-stage process for developing clinical codelists. First, the clear definition a priori of the clinical feature of interest using reliable clinical resources. Second, development of a list of potential codes using statistical software to comprehensively search all available codes. Third, a modified Delphi process to reach consensus between primary care practitioners on the most relevant codes, including the generation of an ‘uncertainty’ variable to allow sensitivity analysis.SettingThese methods are illustrated by developing a codelist for shortness of breath in a primary care EHR sample, including modifiable syntax for commonly used statistical software.ParticipantsThe codelist was used to estimate the frequency of shortness of breath in a cohort of 28 216 patients aged over 18 years who received an incident diagnosis of lung cancer between 1 January 2000 and 30 November 2016 in the Clinical Practice Research Datalink (CPRD).ResultsOf 78 candidate codes, 29 were excluded as inappropriate. Complete agreement was reached for 44 (90%) of the remaining codes, with partial disagreement over 5 (10%). 13 091 episodes of shortness of breath were identified in the cohort of 28 216 patients. Sensitivity analysis demonstrates that codes with the greatest uncertainty tend to be rarely used in clinical practice.ConclusionsAlthough initially time consuming, using a rigorous and reproducible method for codelist generation ‘future-proofs’ findings and an auditable, modifiable syntax for codelist generation enables sharing and replication of EHR studies. Published codelists should be badged by quality and report the methods of codelist generation including: definitions and justifications associated with each codelist; the syntax or search method; the number of candidate codes identified; and the categorisation of codes after Delphi review.
APA, Harvard, Vancouver, ISO, and other styles
17

Jaeckle, Kurt, Karla Ballman, Martin van den Bent, Caterina Giannini, Evanthia Galanis, Paul Brown, Robert Jenkins, et al. "CTNI-29. CODEL: PHASE III TRIAL OF RT ALONE, RT PLUS TMZ, OR TMZ ALONE FOR NEWLY-DIAGNOSED, 1p/19q CODELETED ANAPLASTIC OLIGODENDROGLIOMA. ANALYSIS FROM THE INITIAL STUDY DESIGN. (NCCTG N0577, ALLIANCE)." Neuro-Oncology 22, Supplement_2 (November 2020): ii48—ii49. http://dx.doi.org/10.1093/neuonc/noaa215.196.

Full text
Abstract:
Abstract BACKGROUND The original 3-arm CODEL design included a radiotherapy (RT)-alone control arm, an RT plus temozolomide (TMZ) arm, and an exploratory TMZ-alone arm. We report the analysis involving patients treated per the initial design. METHODS Adults (18+ years) with newly-diagnosed 1p/19q codeleted WHO grade III oligodendroglioma were randomized to RT (5940 cGy) alone (Arm A); RT with concomitant and adjuvant TMZ (Arm B); or TMZ alone (Arm C). Primary endpoint was OS, Arm A vs. B. Secondary comparisons were performed for OS and PFS, comparing pooled RT arms with the TMZ-alone arm. RESULTS 36 patients were randomized equally to the three arms. At median follow-up of 7.5 years, 83.3% (10/12) TMZ-alone patients had progressed, versus 37.5% (9/24) patients on the RT arms. PFS was shorter in TMZ-alone patients compared to RT-treated patients (HR=3.12; 95% CI: 1.26, 7.69; p=0.014). Death from disease progression occurred in 3/12 (25%) of TMZ-alone patients and 4/24 (16.7%) of RT-treated patients. OS did not statistically differ between arms, although this comparison was underpowered. After adjustment for IDH status (mutated vs. wildtype) in a Cox regression model, with IDH status and RT treatment status as co-variables (Arm C vs pooled A and B), PFS remained shorter for patients not receiving RT (HR= 3.33; 95% CI: 1.31, 8.45; p=0.011), and OS differences remained non-significant ((HR = 2.78; 95% CI 0.58, 13.22, p=0.20). Grade 3+ adverse events occurred in 25%, 42% and 33% patients (Arms A, B and C, respectively). Neurocognitive assessments, comparing baseline and 3 month timepoints, showed no significant differences between arms. CONCLUSIONS TMZ-alone treated patients experienced significantly shorter PFS than patients treated on the pooled RT arms, which remained significant when adjusting for IDH status. CODEL has been redesigned to compare the efficacy and toxicity of RT+PCV versus RT+TMZ. Clinicaltrials.gov Identifier: NCT00887146. Support: U10CA180821, U10CA180882, https://acknowledgments.alliancefound.org.
APA, Harvard, Vancouver, ISO, and other styles
18

Touat, Mehdi, Maya Harary, Vasileios Kavouridis, Timothy Smith, and Bryan Iorgulescu. "HOUT-19. THE SHORT-TERM OVERALL SURVIVAL ASSOCIATED WITH SINGLE- VS. MULTI-AGENT CHEMOTHERAPEUTIC REGIMENS FOR 1p/19q-CODELETED WHO GRADE III ANAPLASTIC OLIGODENDROGLIOMAS: A NATIONAL EVALUATION." Neuro-Oncology 21, Supplement_6 (November 2019): vi116. http://dx.doi.org/10.1093/neuonc/noz175.484.

Full text
Abstract:
Abstract INTRODUCTION Although diffuse gliomas of oligodendrocytic lineage demonstrate chemosensitivity, the survival outcomes associated with single- (i.e. temozolomide; TMZ) or multi-agent (i.e. PCV) chemotherapy regimens remain uncertain for anaplastic oligodendrogliomas (AO). METHODS Patients presenting between 2010–2016 with 1p/19q-codeleted WHO grade III AO were identified by ICD-O3 and site-specific factors from the National Cancer Database, which comprises >70% of cancers newly-diagnosed in the U.S. Predictors of receiving first-line single- vs. multi-agent chemotherapy were assessed by multivariable logistic regression. Overall survival (OS) was estimated by Kaplan-Meyer approaches and evaluated by multivariable Cox regression. RESULTS There were 952 patients with 1p/19q-codeleted WHO grade III AO and complete first-line chemotherapy data, with: 13.9% (n=132) no-, 75.0% (n=714) single-, and 11.1% (n=106) multi-agent chemotherapy. In logistic regression of chemotherapy-treated AOs, more recent diagnosis was associated with higher multi-agent (OR=1.48/year, 95%CI=1.25–1.74, p< 0.001) rates; otherwise there were no associations of single- vs. multi-agent chemotherapy with patient sex, age-at-diagnosis, race, insurance status (reference=privately insured), comorbidity index, tumor greatest dimension, tumor location (reference=frontal lobe) or crossing of midline, nor with radiotherapy or EOR (all p >0.05). Multi-agent usage rose from 3.6% in 2010 to 24.3% in 2016. Median follow-up was 34.9mos (IQR=18.8–54.8). The unadjusted 5yr-OS rate was 57.4% (95%CI=43.5–69.1) for no chemotherapy, 72.1% (95%CI=67.1–76.5) for single-agent, and 77.5% (95%CI=59.9–88.1) for multi-agent. Cox regression (adjusting for the above variables of radiotherapy and EOR, patient demographics, and tumor characteristics) demonstrated no significant OS difference between single- and multi-agent (HR=0.91, 95%CI=0.38–2.15, p=0.82) chemotherapy. CONCLUSIONS In a national database of AOs managed in the ‘real-world’ setting, there is increasing utilization of multi-agent (i.e. PCV) chemotherapy; but no significant difference in risk-adjusted short-term mortality (i.e. ~3-5yrs after diagnosis) between first-line multi- and single-agent (i.e. TMZ) chemotherapy. These findings provide preliminary data while we await the long-term PFS and OS results from the CODEL trial.
APA, Harvard, Vancouver, ISO, and other styles
19

Boettiger, Carl. "Generating CodeMeta Metadata for R Packages." Journal of Open Source Software 2, no. 19 (November 13, 2017): 454. http://dx.doi.org/10.21105/joss.00454.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Ducray, F., E. Criniere, A. Idbaih, K. Mokhtari, Y. Marie, S. Paris, S. Navarro, et al. "-Internexin expression identifies 1p19q codeleted gliomas." Neurology 72, no. 2 (January 12, 2009): 156–61. http://dx.doi.org/10.1212/01.wnl.0000339055.64476.cb.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Goyal, Anshit, Yagiz U. Yolcu, Aakshit Goyal, Panagiotis Kerezoudis, Desmond A. Brown, Christopher S. Graffeo, Sandy Goncalves, Terence C. Burns, and Ian F. Parney. "The T2-FLAIR–mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance." Neurosurgical Focus 47, no. 6 (December 2019): E13. http://dx.doi.org/10.3171/2019.9.focus19660.

Full text
Abstract:
OBJECTIVEWith the revised WHO 2016 classification of brain tumors, there has been increasing interest in imaging biomarkers to predict molecular status and improve the yield of genetic testing for diffuse low-grade gliomas (LGGs). The T2-FLAIR–mismatch sign has been suggested to be a highly specific radiographic marker of isocitrate dehydrogenase (IDH) gene mutation and 1p/19q codeletion status in diffuse LGGs. The presence of T2-FLAIR mismatch indicates a T2-hyperintense lesion that is hypointense on FLAIR with the exception of a hyperintense rim.METHODSIn accordance with PRISMA guidelines, we performed a systematic review of the Ovid Medline, Embase, Scopus, and Cochrane databases for reports of studies evaluating the diagnostic performance of T2-FLAIR mismatch in predicting the IDH and 1p/19q codeletion status in diffuse LGGs. Results were combined into a 2 × 2 format, and the following diagnostic performance parameters were calculated: sensitivity, specificity, positive predictive value, negative predictive value, and positive (LR+) and negative (LR−) likelihood ratios. In addition, we utilized Bayes theorem to calculate posttest probabilities as a function of known pretest probabilities from previous genome-wide association studies and the calculated LRs. Calculations were performed for 1) IDH mutation with 1p/19q codeletion (IDHmut-Codel), 2) IDH mutation without 1p/19q codeletion (IDHmut-Noncodel), 3) IDH mutation overall, and 4) 1p/19q codeletion overall. The QUADAS-2 (revised Quality Assessment of Diagnostic Accuracy Studies) tool was utilized for critical appraisal of included studies.RESULTSA total of 4 studies were included, with inclusion of 2 separate cohorts from a study reporting testing and validation (n = 746). From pooled analysis of all cohorts, the following values were obtained for each molecular profile—IDHmut-Codel: sensitivity 30%, specificity 73%, LR+ 1.1, LR− 1.0; IDHmut-Noncodel: sensitivity 33.7%, specificity 98.5%, LR+ 22.5, LR− 0.7; IDH: sensitivity 32%, specificity 100%, LR+ 32.1, LR− 0.7; 1p/19q codeletion: sensitivity 0%, specificity 54%, LR+ 0.01, LR− 1.9. Bayes theorem was used to calculate the following posttest probabilities after a positive and negative result, respectively—IDHmut-Codel: 32.2% and 29.4%; IDHmut-Noncodel: 95% and 40%; IDH: 99.2% and 73.5%; 1p/19q codeletion: 0.4% and 35.1%.CONCLUSIONSThe T2-FLAIR–mismatch sign was an insensitive but highly specific marker of IDH mutation and IDHmut-Noncodel profile, although significant exceptions may exist to this finding. Tumors with a positive sign may still be IDHwt or 1p/19q codeleted. These findings support the utility of T2-FLAIR mismatch as an imaging-based biomarker for positive selection of patients with IDH-mutant gliomas.
APA, Harvard, Vancouver, ISO, and other styles
22

Rosman, Abraham, and Paula Rubel. "Helen Frances Codere (1917-2009)." American Anthropologist 112, no. 2 (May 19, 2010): 342–43. http://dx.doi.org/10.1111/j.1548-1433.2010.01240.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Park, Mingyu, Dongwoo Kim, and Yunja Choi. "CodeAnt : Code Slicing Tool for Effective Software Verification." KIPS Transactions on Software and Data Engineering 4, no. 1 (January 31, 2015): 1–8. http://dx.doi.org/10.3745/ktsde.2015.4.1.1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Núñez-Batalla, Faustino, Carmen Jáudenes-Casaubón, Jose Miguel Sequí-Canet, Ana Vivanco-Allende, Jose Zubicaray-Ugarteche, and Rubén Cabanillas-Farpón. "Aetiological Diagnosis of Child Deafness: CODEPEH Recommendations." Acta Otorrinolaringologica (English Edition) 68, no. 1 (January 2017): 43–55. http://dx.doi.org/10.1016/j.otoeng.2016.05.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Bakholdin, V. S., D. A. Gavrilov, V. A. Dobrikov, and V. F. Ivanov. "Codeless Acquisition of Satellite Navigation System Signals." Giroskopiya i Navigatsiya 27, no. 4 (2019): 147–61. http://dx.doi.org/10.17285/0869-7035.0013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

BANDO, Keita. "ORCID Outreach Meeting and Codefest in Chicago." Journal of Information Processing and Management 57, no. 6 (2014): 423–28. http://dx.doi.org/10.1241/johokanri.57.423.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Pradenas, Lorena, Jorge Zúñiga, and Víctor Parada. "CODELCO, Chile Programs Its Copper-Smelting Operations." Interfaces 36, no. 4 (August 2006): 296–301. http://dx.doi.org/10.1287/inte.1060.0207.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Gomez, Luis A. "The musical instruments in the codexes mixtecos." Journal of the Acoustical Society of America 112, no. 5 (November 2002): 2368. http://dx.doi.org/10.1121/1.4779604.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Wang, Xin, Shu Mao Wang, Na Duan, and Jing Wang. "Study on the Development Platform of Codeless Data Acquisition Software." Applied Mechanics and Materials 195-196 (August 2012): 1125–30. http://dx.doi.org/10.4028/www.scientific.net/amm.195-196.1125.

Full text
Abstract:
In this paper, a codeless data acquisition software development platform (CDASDP), which is written by LabWindows/CVI, is described. This software, based on the idea of software reusing, is a visual codeless programming system with built in support for databases, 2D drawings, ActiveX, etc. Users can develop personalized software by themselves and need not learning or using textural computer languages. Complex programming logic can be simplified into 3 steps such as parameters configuration, user-interface edition, and software creation. By use of CDASDP, development cycle and cost of professional measurement software (PMS) is reduced substantially.
APA, Harvard, Vancouver, ISO, and other styles
30

Schönsteiner, Judith, Vicente Martinez, and Carlos Miranda. "Atribuibilidad al Estado de Chile de actos y omisiones de sus empresas públicas del sector extractivo a la luz de la jurisprudencia de Tribunales Regionales de Derechos Humanos." Revista Chilena de Derecho 47, no. 3 (January 2021): 757–84. http://dx.doi.org/10.7764/r.473.7.

Full text
Abstract:
Este artículo mostrará cómo las dos grandes empresas públicas chilenas que están activas en el rubro extractivo, CODELCO y ENAP, pueden generar responsabilidad internacional del Estado por hechos internacionalmente ilícitos, particularmente, en materia ambiental o de derechos humanos. Para ello, se derivan criterios sobre atribuibilidad de actos y omisiones de CODELCO y ENAP al Estado, a partir del derecho internacional general y la jurisprudencia de tribunales de derechos humanos; estos criterios se aplican a la normativa y práctica administrativa de nuestro país para finalmente concluir que actos y omisiones de las empresas estudiadas efectivamente, son atribuibles al Estado de Chile.
APA, Harvard, Vancouver, ISO, and other styles
31

Trinidad-Ramos, Germán, Valentín Alzina de Aguilar, Carmen Jaudenes-Casaubón, Faustino Núñez-Batalla, and José Miguel Sequí-Canet. "Early hearing detection and intervention: 2010 CODEPEH recommendation." Acta Otorrinolaringologica (English Edition) 61, no. 1 (January 2010): 69–77. http://dx.doi.org/10.1016/s2173-5735(10)70010-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Huang, Dongxu, Dejun Mu, Libin Yang, and Xiaoyan Cai. "CoDetect: Financial Fraud Detection With Anomaly Feature Detection." IEEE Access 6 (2018): 19161–74. http://dx.doi.org/10.1109/access.2018.2816564.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Betz, John W., and Alessandro P. Cerruti. "Performance of dual‐channel codeless and semicodeless processing." Navigation 67, no. 1 (March 2020): 109–28. http://dx.doi.org/10.1002/navi.347.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Borio, Daniele, Marco Rao, and Cillian O'Driscoll. "Codeless processing of binary offset carrier modulated signals." IET Radar, Sonar & Navigation 7, no. 2 (February 2013): 143–52. http://dx.doi.org/10.1049/iet-rsn.2012.0141.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Borio, Daniele. "Cross‐correlation codeless processing of BOC modulated signals." IET Radar, Sonar & Navigation 13, no. 11 (November 2019): 1998–2007. http://dx.doi.org/10.1049/iet-rsn.2019.0018.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Harteloh, Peter. "De gevolgen van automatisch coderen voor de doodsoorzakenstatistiek." Tijdschrift voor gezondheidswetenschappen 95, no. 3 (March 2017): 124–33. http://dx.doi.org/10.1007/s12508-017-0037-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Cairncross, Gregory, Meihua Wang, Edward Shaw, Robert Jenkins, David Brachman, Jan Buckner, Karen Fink, et al. "Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402." Journal of Clinical Oncology 31, no. 3 (January 20, 2013): 337–43. http://dx.doi.org/10.1200/jco.2012.43.2674.

Full text
Abstract:
Purpose Anaplastic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma [AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live longer after chemoradiotherapy is unknown. Patients and Methods Eligible patients with AO/AOA were randomly assigned to procarbazine, lomustine, and vincristine (PCV) plus radiotherapy (RT) versus RT alone. The primary end point was overall survival (OS). Results Two hundred ninety-one eligible patients were randomly assigned: 148 to PCV plus RT and 143 to RT. For the entire cohort, there was no difference in median survival by treatment (4.6 years for PCV plus RT v 4.7 years for RT; hazard ratio [HR] = 0.79; 95% CI, 0.60 to 1.04; P = .1). Patients with codeleted tumors lived longer than those with noncodeleted tumors (PCV plus RT: 14.7 v 2.6 years, HR = 0.36, 95% CI, 0.23 to 0.57, P < .001; RT: 7.3 v 2.7 years, HR = 0.40, 95% CI, 0.27 to 0.60, P < .001), and the median survival of those with codeleted tumors treated with PCV plus RT was twice that of patients receiving RT (14.7 v 7.3 years; HR = 0.59; 95% CI, 0.37 to 0.95; P = .03). For those with noncodeleted tumors, there was no difference in median survival by treatment arm (2.6 v 2.7 years; HR = 0.85; 95% CI, 0.58 to 1.23; P = .39). In Cox models that included codeletion status, the adjusted OS for all patients was prolonged by PCV plus RT (HR = 0.67; 95% CI, 0.50 to 0.91; P = .01). Conclusion For the subset of patients with 1p/19q codeleted AO/AOA, PCV plus RT may be an especially effective treatment, although this observation was derived from an unplanned analysis.
APA, Harvard, Vancouver, ISO, and other styles
38

Eoli, Marica, Valeria Cuccarini, Rosina Paterra, Mariangela Farinotti, Lucia Cuppini, Alessandra Erbetta, Francesco DI Meco, Graziella Filippini, Gaetano Finocchiaro, and Maria Grazia Bruzzone. "Can Diffusion and Perfusion Weighted Imaging predict 1p/19q codeled lower grade gliomas?" Journal of Clinical Oncology 33, no. 15_suppl (May 20, 2015): 2056. http://dx.doi.org/10.1200/jco.2015.33.15_suppl.2056.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

McGeehan, J. E., S. M. R. M. Nezam, P. Saghari, A. E. Willner, R. Omrani, and P. V. Kumar. "Experimental demonstration of OCDMA transmission using a three-dimensional (time-wavelength-polarization) codeset." Journal of Lightwave Technology 23, no. 10 (October 2005): 3282–89. http://dx.doi.org/10.1109/jlt.2005.856302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Tamura, Kaoru, Yaeko Furuhashi, Motoki Inaji, Daisuke Kobayashi, Takahiro Ogishima, Kazutaka Sumita, Yoji Tanaka, Tadashi Nariai, and Taketoshi Maehara. "NI-06 MOLECULAR DIAGNOSIS, 11C-METHIONINE UPTAKE AND PROGNOSIS IN GRADE 2 AND 3 GLIOMAS." Neuro-Oncology Advances 1, Supplement_2 (December 2019): ii26. http://dx.doi.org/10.1093/noajnl/vdz039.119.

Full text
Abstract:
Abstract OBJECT The revised 2016 WHO Classification of Tumours of the Central Nervous System incorporates genetic alterations into the classification system, with the goal of creating more homogenous disease categories with greater prognostic value. In this study, we reclassified 103 consecutive lower grade gliomas using the revised 2016 WHO classification and examined for 11C-methionine uptake and prognosis. METHODS 103 consecutive lower grade glioma patients (Grade 2 in 41 patients, Grade 3 in 62 patients) treated at Tokyo Medical and Dental University Hospital from 2000 to 2018 were included in this study. The IDH1/2, ATRX and 1p19q status were analyzed using tumor samples. The tumor-to-normal ratio (T/N) of 11 C-methionine uptake was calculated by dividing the maximum standardized uptake value (SUV) for the tumor by the mean SUV of the normal brain. RESULT In the integrated diagnosis, 11 astrocytomas and 17 anaplastic astrocytomas were diagnosed as “IDH-mutant”, while 14 astrocytomas and 29 anaplastic astrocytomas were diagnosed as “IDH-wild”. In the 32 oligodendroglial tumors, 12 oligodendrogliomas and 9 anaplastic oligodendrogliomas were diagnosed as “IDH-mutant and 1p/19q-codeleted”. The concordance rate with 1p19q co-deletion and ATRX retention was 94.7%. The median T/N ratios in oligodendroglial tumors with “IDH-mutant and 1p/19q-codeleted” were 1.83 in Grade 2 and 2.83 in grade 3, which were significantly higher than those in astrocytic tumors with “IDH-mutant” (G2: 1.38, G3:1.62). Kaplan-Meier survival analysis revealed that oligodendroglial tumors with “IDH-mutant and 1p/19q-codeleted” had significantly better outcomes regardless of WHO grade. Overall survival was 90.9% at 5 years and 77.9% at 10 years in oligodendroglial tumors with “IDH-mutant and 1p/19q-codeleted”. CONCLUSIONS The results indicated that lower grade glioma categories reclassified with molecular classification correlate with the T/N ratio of methionine and the prognosis.
APA, Harvard, Vancouver, ISO, and other styles
41

Dias, Sara Correa, Francinei Bentes Tavares, and Miquéias Freitas Calvi. "PEDAGOGIA NO CONTEXTO DA POLÍTICA TERRITORIAL: UM ESTUDO DO PROCESSO EDUCATIVO DESENVOLVIDO NO COLEGIADO DE DESENVOLVIMENTO TERRITORIAL (CODETER) DO TERRITÓRIO DA CIDADANIA DO BAIXO TOCANTINS - PA." Revista Margens Interdisciplinar 10, no. 15 (June 9, 2017): 13. http://dx.doi.org/10.18542/rmi.v10i15.4513.

Full text
Abstract:
Este estudo trata dos aspectos educativos desenvolvidos no Colegiado de Desenvolvimento Territorial (CODETER) do Baixo Tocantins (BT), com ênfase nas ações participativas engendradas pelas organizações da sociedade civil e do poder público, no âmbito da gestão social das políticas territoriais. A pesquisa teve como objetivo analisar a influência da participação dos movimentos sociais e das instituições públicas e suas contribuições para a organização política dos agentes sociais que atuam no CODETER. Os procedimentos metodológicos envolveram o uso de metodologias de base qualitativa, como entrevistas semiestruturadas, com a aplicação de questionários. A pesquisa permitiu concluir que o Colegiado encontra-se em uma situação de fragilidade no que diz respeito a participação e a gestão social das políticas públicas.Palavras-chave: Colegiado Territorial, Participação, Baixo Tocantins.
APA, Harvard, Vancouver, ISO, and other styles
42

Tavares, Francinei Bentes, and Monique Medeiros. "Políticas públicas e participação social: uma análise voltada ao Colegiado de Desenvolvimento Territorial do Baixo Tocantins-PA." Redes 25, no. 4 (November 27, 2020): 1628–51. http://dx.doi.org/10.17058/redes.v25i4.14775.

Full text
Abstract:
O presente artigo analisa a efetividade das ações do Colegiado de Desenvolvimento Territorial (CODETER) do Baixo Tocantins-PA, com foco na participação social de atores públicos e da sociedade civil na consolidação de estratégias territoriais. Para o alcance deste objetivo, a pesquisa essencialmente qualitativa, contou com pesquisa bibliográfica, observação participante e 20 entrevistas semiestruturadas. A construção de dados foi realizada em setembro de 2018 e, em um segundo momento, de fevereiro a julho de 2019. Para a análise dos dados utilizou-se a Análise de Conteúdo, a qual permitiu concluir que o CODETER passa, atualmente, por um momento de fragilidade no que diz respeito ao seu processo de funcionamento, principalmente pela falta de participação das entidades da sociedade civil e do poder público. Nas análises ficam evidentes as lamentações dos entrevistados acerca do baixo nível de participação e de assunção de responsabilidade pelos atores regionais para com a política de desenvolvimento territorial. Ademais, os interlocutores confirmam o prevalecimento dos interesses particulares sobre os territoriais na tomada de decisão acerca da alocação de recursos provenientes do Programa de Apoio a Projetos de Infraestrutura e Serviços em Territórios Rurais (PROINF). De modo mais amplo, o que se verifica no contexto analisado é que a maioria dos atores envolvidos com o CODETER não tem uma visão sistêmica do Colegiado, compreendendo-o de forma parcializada, como construção local desarticulada de uma dinâmica territorial.
APA, Harvard, Vancouver, ISO, and other styles
43

Núñez Batalla, Faustino, Carmen Jáudenes Casaubón, José Miguel Sequí Canet, Ana Vivanco Allende, José Zubicaray Ugarteche, and Rubén Cabanillas Farpón. "Diagnóstico etiológico de la sordera infantil: Recomendaciones CODEPEH 2015." REVISTA ESPAÑOLA DE DISCAPACIDAD 4, no. 1 (June 30, 2016): 193–218. http://dx.doi.org/10.5569/2340-5104.04.01.11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Duarte, M., F. Sepúlveda, J. P. Redard, P. Espinoza, V. Lazcano, A. Castillo, A. Zorbas, P. Giménez, and L. Castelli. "Grinding operation optimization of the CODELCO-Andina concentrator plant." Minerals Engineering 11, no. 12 (December 1998): 1119–42. http://dx.doi.org/10.1016/s0892-6875(98)00101-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Gleize, Vincent, Agusti Alentorn, Léa Connen de Kérillis, Marianne Labussière, Aravidan A. Nadaradjane, Emeline Mundwiller, Chris Ottolenghi, et al. "CICinactivating mutations identify aggressive subset of 1p19q codeleted gliomas." Annals of Neurology 78, no. 3 (July 27, 2015): 355–74. http://dx.doi.org/10.1002/ana.24443.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Borio, D. "Squaring and cross-correlation codeless tracking: analysis and generalisation." IET Radar, Sonar & Navigation 5, no. 9 (2011): 958. http://dx.doi.org/10.1049/iet-rsn.2011.0235.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Villa, A., T. Taurino, and W. Ukovich. "Supporting collaboration in European Industrial Districts: the CODESNET approach." Journal of Intelligent Manufacturing 23, no. 6 (February 26, 2011): 2497–506. http://dx.doi.org/10.1007/s10845-011-0516-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Núñez-Batalla, Faustino, Carmen Jáudenes-Casaubón, Jose Miguel Sequí-Canet, Ana Vivanco-Allende, Jose Zubicaray-Ugarteche, and Isabel Olleta Lascarro. "New-born Hearing Screening Programmes in 2020: CODEPEH Recommendations." Acta Otorrinolaringologica (English Edition) 72, no. 5 (September 2021): 312–23. http://dx.doi.org/10.1016/j.otoeng.2020.06.009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Lassman, Andrew, Minhee Won, J. Gregory Cairncross, Edward Shaw, Lynn Ashby, Luis Souhami, Nadia Laack, et al. "ACTR-13. FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402." Neuro-Oncology 21, Supplement_6 (November 2019): vi15. http://dx.doi.org/10.1093/neuonc/noz175.056.

Full text
Abstract:
Abstract BACKGROUND Adding intensive-procarbazine, lomustine, and vincristine (iPCV) to radiotherapy (RT) prolonged progression-free (PFS) and overall survival (OS) for patients with 1p19q codeleted anaplastic oligodendroglial tumors (AOTs); some benefit was also observed for IDH-mutant non-codeleted cases (Cairncross et al 2013, 2014, 2016). Now, 25 years after study activation, we updated survival, further assessed IDH as a predictive biomarker, and are exploring the benefit from vincristine. METHODS Eligible adults (KPS ≥ 60, adequate end-organ function) were randomized to pre-RT iPCV (4 cycles x 6 weeks each) vs. RT alone, stratified by age (< or ≥ 50), KPS (60–70 or ≥ 80), and level of anaplasia. Histology (anaplastic oligodendroglioma/oligo-astrocytoma required) and biomarkers (IDH and 1p19q, post-hoc) were determined centrally. Survival was estimated by Kaplan-Meier and Hazard Ratios (HRs) by Cox-regression. RESULTS Overall (n=289), median follow-up was 16.4 years vs. 11.3 years at last report. In codeleted cases, 40% randomized to iPCV remained alive vs. 53% at last report; 5, 10, and 14 year-PFS and -OS rates were 62%, 50%, 41% and 70%, 57%, 46%, respectively; and iPCV unequivocally prolonged PFS (median 9.8 vs. 2.9 years, HR 0.46, 95% CI 0.3–0.7, p< 0.001) and OS (median 13.2 vs. 7.3 years, HR 0.61, 95% CI 0.40–0.94; p=0.02). With IDH mutation but without codeletion (n=66), iPCV prolonged PFS (median 2.8 vs. 1.9 years, HR 0.58, 95% CI 0.34–0.99, p=0.046); OS was longer with a trend for significance (median 5.5 vs. 3.3 years, HR 0.6, 95% CI 0.34–1.03, p=0.06) on this underpowered exploratory post-hoc analysis. CONCLUSION For codeleted AOTs, long-term analyses confirmed that pre-RT iPCV produced meaningful and significant prolongations of PFS and OS. With IDH mutation but without codeletion, iPCV significantly prolonged PFS and showed a trend for prolonged OS. The value of vincristine is being assessed. Supported by NCI grants U10CA180868, U10CA180822, U24CA196067, and UG1CA189867.
APA, Harvard, Vancouver, ISO, and other styles
50

Rudà, Roberta, Alessia Pellerino, Andrea Pace, Carmine Maria Carapella, Cristina Dealis, Manuela Caroli, Marina Faedi, et al. "ACTR-20. EFFICACY OF INITIAL TEMOZOLOMIDE FOR HIGH-RISK LOW GRADE GLIOMAS IN A PHASE II AINO (ITALIAN ASSOCIATION FOR NEURO-ONCOLOGY) STUDY: A POST-HOC ANALYSIS WITHIN MOLECULAR SUBGROUPS OF WHO 2016." Neuro-Oncology 21, Supplement_6 (November 2019): vi16—vi17. http://dx.doi.org/10.1093/neuonc/noz175.063.

Full text
Abstract:
Abstract BACKGROUND The optimal management of high risk WHO grade II gliomas after surgery is still debated. The efficacy of initial temozolomide to delay radiotherapy and risk of cognitive defects could vary across the molecular subgroups of WHO 2016, but information on this issue are lacking. PATIENTS AND METHODS A post-hoc analysis has been performed on a cohort of high risk WHO grade II gliomas, who received initial temozolomide alone in phase II multicenter study, with the objective of re-evaluating the long-term results across the different molecular subgroups of the WHO 2016 classification. The primary endpoint of the study, carried out between 2007 and 2010, was response rate according to RANO, being seizure response, PFS and OS secondary endpoints. RESULTS Response rate (partial and minor responses) among oligodendrogliomas IDH-mutant and 1p/19q codeleted (76%) was significantly higher than that among diffuse astrocytomas either mutant (55%) or wild-type (36%). A reduction of seizure frequency >50% was observed in 87% patients and a seizure freedom in 72%. The probability of seizure reduction >50% was significantly associated with the presence of an IDH mutation. Median PFS, PFS at 5 and 10 years, median OS and OS at 5 and 10 years were all significantly longer in oligodendrogliomas IDH-mutant and 1p/19q codeleted. Of patients who did not recur or delay radiotherapy at recurrence for a median follow-up of 8.2 years, 67% and 59%, respectively, were oligodendrogliomas IDH-mutant and 1p/19q codeleted. CONCLUSIONS The post-hoc analysis of this phase II trial suggests that the beneficial effects of initial temozolomide prevail in oligodendrogliomas IDH-mutant and 1p/19q codeleted: thus, these tumors, when incompletely resected or progressive after surgery, especially when suffering from pharmacoresistant seizures, could receive temozolomide as initial treatment with radiotherapy and chemotherapy at recurrence. The trial was registered with EU Clinical Trials Register, EudraCT n. 2007/000386-38.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Codelet' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography